In an ongoing, open label, Phase I trial, an anti-PSMA/CD70 bi-specific CAR-T cell therapy has been tested in several cancer types (including TNBC) expressing PSMA or CD70, another potential tumor target, that is overexpressed in many cancer types and scarcely expressed in normal tissue (NCT05437341). The gene discussed is FOLH1; the disease is neoplasm.